SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation ...

Topline data is expected in mid-2025, marking a key milestone in the development of a needle-free, shelf-stable pill vaccine to address norovirus, a leading global cause of acute gastroenteritis.

April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs ...

The company maintains a cash runway into the fourth quarter of 2025 and continues its focus on advancing its norovirus and other vaccine programs. Vaxart’s strategic efforts include exploring ...

Norovirus is highly contagious, often spread by food or on surfaces, particularly in crowded conditions. It is a short-lived ...

The company maintains a cash runway into the fourth quarter of 2025 and continues its focus on advancing its norovirus and other vaccine programs. Vaxart’s strategic efforts include exploring ...